Beacon Therapeutics’ gene therapy shows 12-month benefit

Beacon is investigating the gene therapy in other pivotal trials, including the VISTA trial that is expected to readout in H2 2026. Beacon is investigating the gene therapy in other pivotal trials, including the VISTA trial that is expected to readout in H2 2026. Beacon Therapeutics reported the data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting held 3-7 May 2026 in Denver, Colorado. Credit: Corona Borealis Studio / Shutterstock.com Beacon Therapeutics’ gene therapy has shown a 12-month benefit in a Phase II study in patients with X-linked retinitis pigmentosa (XLRP), a rare type of inherited…

Source: Clinical Trials Arena